Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reiterated by research analysts at Stifel Nicolaus in a research report issued to clients and investors on Wednesday. They presently have a GBX 800 ($10.44) target price on the stock. Stifel Nicolaus’ target price suggests a potential upside of 17.13% from the company’s current price.
Several other analysts have also commented on the stock. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 933 ($12.18) price target on shares of Clinigen Group PLC in a research report on Wednesday. N+1 Singer reaffirmed a “buy” rating and set a GBX 800 ($10.44) price target on shares of Clinigen Group PLC in a research report on Wednesday. Finally, Peel Hunt reaffirmed a “buy” rating and set a GBX 1,000 ($13.05) price target on shares of Clinigen Group PLC in a research report on Wednesday. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of GBX 856.60 ($11.18).
Shares of Clinigen Group PLC (LON:CLIN) opened at 691.50 on Wednesday. The company’s market cap is GBX 771.71 million. The firm’s 50-day moving average price is GBX 653.77 and its 200 day moving average price is GBX 598.48. Clinigen Group PLC has a 12 month low of GBX 492.75 and a 12 month high of GBX 739.50.
The firm also recently declared a dividend, which will be paid on Friday, November 25th. Shareholders of record on Thursday, November 3rd will be paid a GBX 2.70 ($0.04) dividend. This is an increase from Clinigen Group PLC’s previous dividend of $1.30. The ex-dividend date is Thursday, November 3rd. This represents a dividend yield of 0.38%.
About Clinigen Group PLC
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.